Copyright
©The Author(s) 2016.
World J Gastroenterol. Jun 21, 2016; 22(23): 5445-5453
Published online Jun 21, 2016. doi: 10.3748/wjg.v22.i23.5445
Published online Jun 21, 2016. doi: 10.3748/wjg.v22.i23.5445
Table 1 Characteristics of included studies
Ref. | Inclusion criteria | Region | Diagnostic test | No. of patients (male %) | Age, yr(mean ± SD) | Intervention |
Ang et al[36] (2015) | Age > 21 yr | Singapore | RUT, H, UBT | C10: 153 (47.1) | C10: 46.9 ± 14.8 | 10-d concomitant therapy |
S10: 154 (59.7) | S10: 47.5 ± 12.7 | 10-d sequential therapy | ||||
T10: 155 (58.1) | T10: 49.8 ± 14.6 | 10-d triple therapy | ||||
Hsu et al[33] (2014) | Age ≥ 20 yr, PU or gastritis | Taiwan | RUT, Cu, H | C7: 102 (59.8) | C7: 53.9 ± 12.3 | 7-d concomitant therapy |
S10: 102 (50.9) | S10: 55.0 ± 12.0 | 10-d sequential therapy | ||||
T7: 103 (60.2) | T7: 56.1 ± 14.0 | 7-d triple therapy | ||||
Huang et al[22] (2012) | Dyspepsia or epigastric discomfort | Taiwan | RUT, Cu, H | C10: 84 (57.1) | C10: 53.8 ± 15.2 | 10-d concomitant therapy |
S10: 85 (56.7) | S10: 51.3 ± 15.0 | 10-d sequential therapy | ||||
Tai et al[34] (2015) | Age ≥ 20 yr, PU or gastritis | Taiwan | Not reported | C7: 92 (50.0) | C7: 47.8 ± 11.6 | 7-d concomitant therapy |
T7: 92 (49.0) | T7: 52.8±12.8 | 7-d triple therapy | ||||
Wang et al[35] (2014) | PU and gastritis | China | UBT | C7: 81 (45.7) | C7: 51 ± 13 | 7-d concomitant therapy |
T7: 82 (42.7) | T7: 51 ± 15 | 7-d triple therapy | ||||
T10: 83 (45.8) | T10: 52 ± 14 | 10-d triple therapy | ||||
Wu et al[20] (2010) | Patients visited GI clinics with HP infection | Taiwan | RUT, Cu, H | C10: 115(52.2) | C10: 51.8 ± 11 | 10-d concomitant therapy |
S10:117(52.1) | S10: 51.7 ± 12 | 10-d sequential therapy |
Table 2 Assessment of methodological quality of included studies
Ref. | Region | Allocation generation | Allocation concealment | Blinding of patients and assessors | Data analysis | Loss to follow up | Selective reporting | Other bias |
Ang et al[36] (2015) | Singapore | Sealed envelope | Adequate | Open-label | ITT/PP | 10.0% | Low risk | Not all patients underwent antibiotic susceptibility testing |
Hsu et al[33] (2014) | Taiwan | Compute generated | Adequate | Open-label | ITT/PP | 0.3% | Low risk | Not all patients underwent antibiotic susceptibility testing |
Huang et al[22] (2012) | Taiwan | Computer generated | Unclear | Open-label | ITT/PP | 6.5% | Low risk | No patient underwent antibiotic susceptibility testing |
Tai et al[34] (2015) | Taiwan | Computer generated | Adequate | Unclear | ITT/PP | 8.0% | Low risk | Not all patients underwent antibiotic susceptibility testing |
Wang et al[35] (2014) | China | Computer generated | Unclear | Unclear | ITT/PP | 1.2% | Low risk | No patient underwent antibiotic susceptibility testing |
Wu et al[20] (2010) | Taiwan | Computer generated | Unclear | Outcome assessor blinded | ITT/PP | 0.4% | Low risk | Not all patients underwent antibiotic susceptibility testing |
- Citation: Lin LC, Hsu TH, Huang KW, Tam KW. Nonbismuth concomitant quadruple therapy for Helicobacter pylori eradication in Chinese regions: A meta-analysis of randomized controlled trials. World J Gastroenterol 2016; 22(23): 5445-5453
- URL: https://www.wjgnet.com/1007-9327/full/v22/i23/5445.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i23.5445